<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04039022</url>
  </required_header>
  <id_info>
    <org_study_id>AXS-05-303</org_study_id>
    <nct_id>NCT04039022</nct_id>
  </id_info>
  <brief_title>Open-Label Safety Study of AXS-05 in Subjects With Depression</brief_title>
  <official_title>An Open-Label Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects With Major Depressive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Axsome Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Axsome Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open-label, long-term, safety study of AXS-05 in patients with major depressive disorder
      (MDD), including treatment resistant depression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A multi-center, open-label, long-term study to evaluate the safety and efficacy of AXS-05 in
      patients with major depressive disorder, including treatment resistant depression, treated
      for up to one year.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 8, 2019</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Types and rates of adverse events</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Safety</description>
  </primary_outcome>
  <other_outcome>
    <measure>Montgomery-Ã…sberg Depression Rating Scale (MADRS)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>The MADRS is a clinician-rated scale designed to measure depression severity and detects changes due to antidepressant treatment. The scale consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Major Depressive Disorder</condition>
  <condition>Treatment Resistant Depression</condition>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>AXS-05 (dextromethorphan and bupropion)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AXS-05</intervention_name>
    <description>Oral tablets, taken twice daily for up to 12 months.</description>
    <arm_group_label>AXS-05 (dextromethorphan and bupropion)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of major depressive disorder, including treatment resistant depression

          -  Body mass index (BMI) between 18 and 40 kg/m^2, inclusive

          -  Agree to use adequate method of contraception for the duration of the study

          -  Additional criteria may apply

        Exclusion Criteria:

          -  Suicide risk

          -  Pregnant, breastfeeding, or planning to become pregnant or breastfeed during the study

          -  Additional criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Trial Manager</last_name>
    <phone>212-332-3241</phone>
    <email>ajones@axsome.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Axsome Study Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 29, 2019</study_first_submitted>
  <study_first_submitted_qc>July 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2019</study_first_posted>
  <last_update_submitted>August 22, 2019</last_update_submitted>
  <last_update_submitted_qc>August 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Depression</keyword>
  <keyword>AXS-05</keyword>
  <keyword>Dextromethorphan</keyword>
  <keyword>Bupropion</keyword>
  <keyword>Dopamine Reuptake Inhibitor</keyword>
  <keyword>NMDA Receptor Antagonist</keyword>
  <keyword>Nicotinic Acetylcholine Receptor Antagonist</keyword>
  <keyword>Serotonin Reuptake Inhibitor</keyword>
  <keyword>Axsome Therapeutics</keyword>
  <keyword>Norepinephrine Reuptake Inhibitor</keyword>
  <keyword>Sigma-1 Receptor Agonist</keyword>
  <keyword>Glutamate Modulator</keyword>
  <keyword>Antidepressant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
    <mesh_term>Depressive Disorder, Treatment-Resistant</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

